[Magnesium deficiency and therapy in cardiac arrhythmias: recommendations of the German Society for Magnesium Research]. / Magnesiummangel und Magnesiumtherapie bei Herzrhythmusstörungen. Empfehlungen der Gesellschaft für Magnesium-Forschung e. V.

Aim of the recommendations of the German Society for Magnesium Research: Recognition and compensation of magnesium deficiency in patients with risk factors for cardiac arrhythmias or manifest rhythm disturbances. Prevention of arrhythmias by administration of magnesium. Therapeutic administration of magnesium in patients with arrhythmias with and without magnesium deficiency. The current state of knowledge claims for considering the status of magnesium and the possibility of a therapeutic intervention with magnesium within the concept of the treatment of cardiovascular diseases. The use of magnesium as single agent or as an adjunct to other therapeutic actions in the prevention and therapy of cardiac arrhythmias can be effective and, in case of oral administration, very safe. In case of parenteral administration, it is important to use adequate doses, monitor cardiovascular and neuromuscular parameters and to consider contraindications.

Follow-up of needlesticks in medical staff.

In an on-going study, 104 events of needlestick or contamination of apparent skin lesions were evaluated for the risk of hepatitis. Whenever possible, a blood sample of the 'donor' was screened for HBsAg as well as for elevated transaminases. Members of the staff were bled immediately after exposure and were followed up for 9 months. At present the follow-up is completed in twenty probands. - Hepatitis B immunoglobulin (= HBIG) was given in 51 cases. HBsAg was detected in 21 donors and strongly supposed in 27 cases. Only one nurse developed acute hepatitis B ten months after exposure to HBsAg-positive blood. 53 probands were exposed to HBsAg-negative blood. 32 persons received SIG. Only 5 'donors' were classified as probable Non-A, Non-B hepatitis which did not induce apparent infections in passively immunized persons. 23 persons did receive neither HBIG nor SIG. 2 persons had been exposed to HBsAg-positive blood by needlestick, still being without seroconversion. Passive immunization after needlestick should be performed after testing blood samples of donors and recipient. After exposure to non-A, non-B hepatitis, secondary infections did not appear in passively immunized persons.

Hepatitis markers in a psychiatric institution.

Hepatitis A and B markers were determined in 714 patients and in 291 members of the staff of a psychiatric institution for adults. The leading diagnosis were psychosis (71.8%), neurosis (17.7%), and oligophrenia (10.6%). Anti-HAV was found in 84.4% of the patients and in 69.2% of the staff. 26.8% of the patients and 19.9% of the staff had at least one HBV marker. The frequency of HBV markers correlated with the age of the patients but not with the duration of the hospitalization. After the exclusion of IgM-anti-HAV, IgM-anti-CMV and IgM-anti-EBV or possible toxic effects, 2.6% of all patients remained as presumable non-A, non-B hepatitis infections. In this study HBV markers were not found in an hyperendemic pattern reported previously in psychiatric institutions.

Non-A, non-B hepatitis in hemodialysis.

Episodes of presumable non-A, non-B hepatitis were determined among hemodialysis patients during a two year period as well as possible secondary infections in household contacts. We determined hepatitis A and B markers by commercial RIA kits, and IgM-anti-CMV and IgM-anti-EBV by ELISA techniques. 154 dialysis patients, 118 relatives of patients, and 42 members of the staff were included in the study. 71% of the center dialysis patients, 63% of the home dialysis patients, 50% of the staff, and 19% of the relatives were HBV marker positive. Spouses of patients more often had HBV markers than other relatives. Anti-HAV was highly prevalent both in center patients (98.8%) and in home dialysis patients (83.3%). The incidence of IgM-anti-CMV was marked in home dialysis patients (15.5%). During a two year period, 9% of all dialysis patients had an episode of presumable non-A, non-B hepatitis. As compared to previous data in the same dialysis centers, there is a change in the epidemiology of hepatitis.

Viral hepatitis A and B in hemodialysed patients.

In 113 hemodialysed patients, 167 hospitalized patients, and 143 outpatients the frequency of HAV and HBV markers were studied by testing HBsAg, anti-HBs, anti-HBc, HBeAg, anti-HBe, and anti-HAV. The hemodialysis patients in a dialysis-center had significantly more often HBV markers (85.7%) than those maintained on home-dialysis (46.5%). 29.9% of the hospitalized patients and 32.1% of the outpatients had HBV markers. By the anti-HBc test up to 41% of additional HBV infections could be detected.--The prevalence of anti-HAV was very high in all groups. Significant differences between the hemodialysis patients and the control groups existed only in the age groups up to 39 years.--The frequencies of HAV and HBV markers were related to age, duration of dialysis treatment, transfusional frequency, and transaminases. The HBV appeared as the clinically important hepatitis agent in dialysis.

Intranuclear virus-like particles in a case of sporadic non-A, non-B hepatitis.

A case of acute hepatitis type non-A, non-B in a 20-year-old woman is reported. Virus-like particles with a size of about 27 nm in diameter could be identified by electron microscopy in numerous hepatocellular nuclei. They are thought to represent one candidate for the intranuclear form of a non-A, non-B hepatitis virus.